#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Duchenne muscular dystrophy gene carrier Cholangiocarcinoma Scedosporium infection Solitary fibrous tumour Malignant oligodendroglioma Pulmonary alveolar haemorrhage Transient ischaemic attack Nephropathy Skin angiosarcoma NTRK gene fusion overexpression Neoplasm Synovial sarcoma recurrent B-cell lymphoma recurrent Epileptic encephalopathy Phenylketonuria More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma – Trials in Disease Aicardi-Goutieres syndrome – Treatment Loeys-Dietz syndrome – Trials in Disease Pemphigus – Treatment Congenital generalised lipodystrophy – Treatment Hypereosinophilic syndrome – Trials in Disease Brain stem glioma CADASIL – Trials in Disease Haemophilia – Treatment Retinoblastoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Specific Nucleic Acid Sna-Xfsa ANERATRIGINE MESILATE Meropenem Trihydrate Bi 706321 Simeticone Aciclovir GSKVX000000039711 LUNRESERTIB Dextran 70 Mexiletine Hydrochloride ZALFERMIN Tozinameran Tipapkinogene Sovacivec Lactose SODIUM TETRACHLOROPALLADATE Bendamustine Hydrochloride ARI0008 Nitrous Oxide Io102 Hydrochloride Keto-Isoleucine Calcium More therapies…

    Learn about Your Condition

    Oropharyngeal cancer Pruritus Alveolar rhabdomyosarcoma Hepatic neoplasm Head injury Chronic hepatic failure Syphilis Polyneuropathy Cervix carcinoma Cutaneous calcification Cholangiosarcoma Testis cancer Sarcoma metastatic Synovial sarcoma recurrent Vaginal haemorrhage More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

    Recruiting

    2 1
    Investigated Drugs:
    • Ro7790121
    Belgium Denmark France Germany Italy Poland +1

  • A Study of Maribavir for Cytomegalovirus Infection in Stem Cell Transplant Patients Who Cannot Take or Did Not Tolerate Standard Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Cytomegalovirus infection
    • Allogenic stem cell transplantation
    Investigated Drugs:
    • Maribavir
    Italy

  • A Study of ALXN1920 Compared to Placebo in Adults with Primary Membranous Nephropathy at High Risk for Disease Progression

    Recruiting

    2 1
    Investigated Diseases:
    • Nephropathy
    Investigated Drugs:
    • ALXN1920
    France Italy Spain

  • A Study Testing Imeroprubart for Adults with Primary Sjogren’s Disease with Moderate to Severe Symptoms

    Recruiting

    2 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • IMEROPRUBART
    Germany Greece Hungary Italy Poland Romania +1

  • A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

    Recruiting

    3 1
    Belgium France Germany Italy The Netherlands Poland +1

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Leuprorelin
    • Anastrozole
    France Germany Italy The Netherlands Spain
Previous Page
1 … 99 100 101 102 103 … 1,646
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!